A Study of Apatinib in Recurrent or Recurrent High-grade Glioma

Sponsor
West China Hospital
Study ID
NCT03390062
Phase
PHASE2
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Apatinib — DRUG
    Apatinib, also known as YN968D1, is a tyrosine kinase inhibitor that selectively inhibits the vascular endothelial growth factor receptor-2 (VEGFR2, also known as KDR). It is an orally bioavailable, small molecule agent which is thought to inhibit angiogenesis in cancer cells; specifically apatinib inhibits VEGF-mediated endothelial cell migration and proliferation thus blocking new blood vessel formation in tumor tissue.

Study Details

The purpose of this study is to determine the effectiveness and safety of Apatinib for patients with Recurrent or Recurrent High-grade Glioma.

Key Dates

Start date
Jan 4, 2018
Status verified
Dec 2017
Primary completion
Dec 20, 2019
Completion
Aug 1, 2020

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: apatinib
    apatinib 500 mg orally daily until the untolerabale toxicities、desease progress or death

Primary Outcome Measure

Overall Survival(OS) [ Time Frame: 24 month ]

Central Contacts

Related Studies